Home Cart Sign in  
Chemical Structure| 935881-37-1 Chemical Structure| 935881-37-1

Structure of AR-42
CAS No.: 935881-37-1

Chemical Structure| 935881-37-1

AR-42

CAS No.: 935881-37-1

AR-42 is an inhibitor ofHDAC with IC50 30 nM.

Synonyms: HDAC-42; OSU-HDAC42; OSU-42

4.5 *For Research Use Only !

Cat. No.: A374120 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łËó¶ÊÊ Inquiry Inquiry
5mg łÿď¶ÊÊ Inquiry Inquiry
10mg łóÿ¶ÊÊ Inquiry Inquiry
25mg łÇÍʶÊÊ Inquiry Inquiry
50mg łË§ò¶ÊÊ Inquiry Inquiry
100mg ł§ó˶ÊÊ Inquiry Inquiry
250mg łòÍǶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łËó¶ÊÊ

  • 5mg

    łÿď¶ÊÊ

  • 10mg

    łóÿ¶ÊÊ

  • 25mg

    łÇÍʶÊÊ

  • 50mg

    łË§ò¶ÊÊ

  • 100mg

    ł§ó˶ÊÊ

  • 250mg

    łòÍǶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AR-42

CAS No. :935881-37-1
Formula : C18H20N2O3
M.W : 312.36
SMILES Code : O=C(NO)C1=CC=C(NC([C@H](C2=CC=CC=C2)C(C)C)=O)C=C1
Synonyms :
HDAC-42; OSU-HDAC42; OSU-42
MDL No. :MFCD17676151
InChI Key :LAMIXXKAWNLXOC-INIZCTEOSA-N
Pubchem ID :6918848

Safety of AR-42

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of AR-42

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC

    HDAC, IC50:30 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Kasumi-1, NB4, and FDC-P1-KITmut cells 0.3 μM to 1 μM 72 h or 48 h To assess the effects of AR-42 on cell proliferation and miR-29b expression. PMC3764604
SW780 cells 5 μM 24 hours The combination of AR-42 and cisplatin synergistically destroyed bladder cancer cells via apoptosis. PMC6371809
HT1376 cells 5 μM 24 hours The combination of AR-42 and cisplatin synergistically destroyed bladder cancer cells via apoptosis. PMC6371809
THP-1 cells 2 μM 24 hours To evaluate the effect of AR-42 on miR-199b expression in THP-1 cells, results showed that AR-42 significantly elevated miR-199b expression. PMC4740997
MOLM13 cells 0.1 μM 48 hours AR-42 and KPT-9274 co-treatment significantly reduced the survival of MOLM13 cells, showing synergistic effects. PMC8054771
Kasumi-1 cells 0.1 μM 48 hours AR-42 and KPT-9274 co-treatment significantly reduced the survival of Kasumi-1 cells, showing synergistic effects. PMC8054771
Ben-Men-1 cells 1μM 2 days AR-42 inhibited the proliferation of Ben-Men-1 cells by increasing the expression of p16INK4A, p21CIP1/WAF1, and p27KIP1, and induced G2/M cell cycle arrest. PMC3549000
normal meningeal cells 1μM 2 days AR-42 inhibited the proliferation of normal meningeal cells by increasing the expression of p16INK4A, p21CIP1/WAF1, and p27KIP1, and induced G1 cell cycle arrest. PMC3549000
mouse embryonic fibroblasts 5 µM 24 hours H3K4me3 reporter activity was reduced in Kmt2d+/βGeo cells but normalized after AR-42 treatment PMC4406328

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice C-26 colon adenocarcinoma and LLC models Oral 50 mg/kg every other day, 11 days AR-42 significantly mitigated body weight loss and muscle atrophy, improved survival rates, and maintained muscle mass in tumor-bearing mice. PMC6280990
CD2F1 mice C-26 tumor model Oral gavage 10 mg/kg Once daily for 13 days To evaluate the anti-cachectic effects of AR-42, results showed that AR-42 significantly improved body weight, hindlimb muscle mass, and grip strength in the C-26 model. PMC7005646
NSG mice subcutaneous xenograft model Intraperitoneal injection 50 mg/kg 3 times per week for AR-42, once weekly for cisplatin, continued treatment The combination of AR-42 and cisplatin significantly reduced tumor growth and size. PMC6371809
Mice Mll4 mutant mouse models Intraperitoneal injection 50 mg/kg daily, from 9 days post-conception until embryo harvest AR-42 restored the expression of GHRH neurons in Mll4-deficient mice, partially repairing the developmental program of GHRH neurons PMC7801453
NCG mice MOLM13 xenograft model Oral gavage 20 mg/kg Every other day, continued treatment AR-42 and KPT-9274 combination therapy significantly prolonged the survival of MOLM13 xenograft mice and reduced leukemic cell infiltration. PMC8054771
SCID C.B17 mice intracranial xenograft model Oral 25mg/kg/day daily for 6 months AR-42 significantly inhibited the growth of Ben-Men-1-LucB tumors, leading to tumor regression, and showed minimal regrowth after treatment cessation. PMC3549000
Kmt2d+/βGeo mice mouse model of Kabuki syndrome Oral 10 mg/kg/day daily for 14 days AR-42 treatment improved H3K4me3 deficiency and hippocampal memory defects in Kmt2d+/βGeo mice PMC4406328

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01798901 Adult Acute Myeloid Leukemia W... More >>ith 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 1 Completed - United States, Ohio ... More >> Cincinnati Children's Hospital Cincinnati, Ohio, United States, 45229 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT01129193 Adult Nasal Type Extranodal NK... More >>/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Hepatosplenic T-cell Lymphoma Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Peripheral T-cell Lymphoma Post-transplant Lymphoproliferative Disorder Prolymphocytic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Multiple Myeloma Stage III Adult Burkitt Lymphoma Stage III Adult Diffuse Large Cell Lymphoma Stage III Adult Diffuse Mixed Cell Lymphoma Stage III Adult Diffuse Small Cleaved Cell Lymphoma Stage III Adult Hodgkin Lymphoma Stage III Adult Immunoblastic Large Cell Lymphoma Stage III Adult Lymphoblastic Lymphoma Stage III Adult T-cell Leukemia/Lymphoma Stage III Chronic Lymphocytic Leukemia Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma Stage III Grade 3 Follicular Lymphoma Stage III Mantle Cell Lymphoma Stage III Marginal Zone Lymphoma Stage III Multiple Myeloma Stage III Mycosis Fungoides/Sezary Syndrome Stage III Small Lymphocytic Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Adult T-cell Leukemia/Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Mycosis Fungoides/Sezary Syndrome Stage IV Small Lymphocytic Lymphoma Testicular Lymphoma Waldenstrom Macroglobulinemia Less << Phase 1 Completed - United States, Ohio ... More >> The Ohio State University James Cancer Hospital Columbus, Ohio, United States, 43210 Less <<
NCT02569320 Recurrent Plasma Cell Myeloma Phase 1 Suspended(Internal data analys... More >>is) Less << March 31, 2019 United States, Ohio ... More >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Less <<
NCT02795819 Renal Cell Carcinoma ... More >> Soft Tissue Sarcoma Metastatic Disease Less << Phase 1 Active, not recruiting June 30, 2025 United States, Virginia ... More >> Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less <<
NCT02282917 Vestibular Schwannoma|Meningio... More >>ma|Acoustic Neuroma|Neurofibromatosis Type 2 Less << EARLY_PHASE1 TERMINATED 2021-01-04 Stanford University, Stanford,... More >> California, 94305, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Massachusetts Eye and Ear, Boston, Massachusetts, 02214, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.20mL

0.64mL

0.32mL

16.01mL

3.20mL

1.60mL

32.01mL

6.40mL

3.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories